Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099397 | 0.99 | MGLL (0.48) | MGLLHDAC4HDAC6P2RX3GRM5 | |
| SCHEMBL3095455 | 0.85 | P2RX3 (0.44) | MGLLHDAC4P2RX3GPR119 | |
| SCHEMBL378815 | 0.84 | GPR119 (0.44) | MGLLHDAC4HDAC6P2RX3GPR119 | |
| SCHEMBL7908887 | 0.81 | GRM5 (0.45) | MGLLHDAC4HDAC6GRM5CLPP | |
| SCHEMBL13092275 | 0.80 | GRM5 (0.45) | MGLLHDAC4HDAC6GRM5CLPP | |
| SCHEMBL7071414 | 0.78 | FASN (0.60) | MGLLHDAC4HDAC6GRM5CLPP | |
| SCHEMBL3101440 | 0.78 | HSD11B1 (0.53) | HSD11B1MEN1KMT2A | |
| SCHEMBL3099478 | 0.78 | MGLL (0.55) | MGLLHDAC4HDAC6PLK1HDAC2 | |
| SCHEMBL7649427 | 0.77 | SMYD3 (0.54) | MGLLHDAC4HDAC6PLK1SMYD3 | |
| SCHEMBL3092569 | 0.77 | HSD11B1 (0.54) | MGLLHSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324250-B2 | Piperidine derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256126-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HTR3A, OPRL1, OPRK1 | MGLL 3999/4885HDAC4 1271/4885HDAC6 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.